Novo Nordisk A/S (NYSE:NVO) went up by 0.21% from its latest closing price compared to the recent 1-year high of $75.86. The company’s stock price has collected -3.66% of loss in the last five trading sessions. MarketWatch.com reported on 02/11/21 that Diabetes drug hailed as a breakthrough for weight loss
Is It Worth Investing in Novo Nordisk A/S (NYSE :NVO) Right Now?
Novo Nordisk A/S (NYSE:NVO) scored a price-to-earnings ratio above its average ratio, recording 24.70 x from its present earnings ratio. Plus, the 36-month beta value for NVO is at 0.46. Opinions of the stock are interesting as 13 analysts out of 32 who provided ratings for Novo Nordisk A/S declared the stock was a “buy,” while 2 rated the stock as “overweight,” 11 rated it as “hold,” and 5 as “sell.”
The average price from analysts is $75.17, which is $5.09 above the current price. NVO currently public float of 1.26B and currently shorts hold a 0.34% ratio of that float. Today, the average trading volume of NVO was 1.08M shares.
NVO’s Market Performance
NVO stocks went down by -3.66% for the week, with a monthly drop of -1.27% and a quarterly performance of 7.33%, while its annual performance rate touched 18.40%. The volatility ratio for the week stands at 1.08% while the volatility levels for the past 30 days are set at 1.39% for Novo Nordisk A/S. The simple moving average for the period of the last 20 days is 0.02% for NVO stocks with a simple moving average of 6.20% for the last 200 days.
NVO Trading at 1.15% from the 50-Day Moving Average
After a stumble in the market that brought NVO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -4.64% of loss for the given period.
Volatility was left at 1.39%, however, over the last 30 days, the volatility rate increased by 1.08%, as shares surge +3.39% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +4.03% upper at present.
During the last 5 trading sessions, NVO fell by -3.66%, which changed the moving average for the period of 200-days by +13.07% in comparison to the 20-day moving average, which settled at $72.44. In addition, Novo Nordisk A/S saw 3.56% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for NVO
Current profitability levels for the company are sitting at:
- +38.32 for the present operating margin
- +80.43 for the gross margin
The net margin for Novo Nordisk A/S stands at +35.69. The total capital return value is set at 66.66, while invested capital returns managed to touch 66.45. Equity return is now at value 71.00, with 30.80 for asset returns.
Based on Novo Nordisk A/S (NVO), the company’s capital structure generated 16.35 points at debt to equity in total, while total debt to capital is 14.06. Total debt to assets is 7.15, with long-term debt to equity ratio resting at 4.57. Finally, the long-term debt to capital ratio is 3.93.
When we switch over and look at the enterprise to sales, we see a ratio of 8.44, with the company’s debt to enterprise value settled at 0.01. The receivables turnover for the company is 4.39 and the total asset turnover is 0.87. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.94.